← boardnext 2026-12next 2027-11next 2028-10next 2029-03
UTHR
United Therapeuticsdistress 0/10 · well-funded / low risk$524.540%today-12% from 52w high
Lead: idiopathic pulmonary fibrosis · est. market ~$5B (approx, global)
Revenue
$782M
Liquidity
$3471M
Runway
—
Shares 1y
-6%
Price & events
+11.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.5%
1D
-0.9%
1W
-3.6%
1M
-8.4%
3M
+11.9%
6M
+71.6%
1Y
+55.8%
2Y
+184.2%
5Y
+240.7%
All
Overview
- Market Cap
- $22.27B
- Volume
- 12.78K
- 52 Week Range
- $275 – $597
- Total Shares
- 42.45M
- Float Shares
- 38.91M
- Short %
- 5.84%
- % Held by Insiders
- 2.05%
- % Held by Institutions
- 101.92%
- RVOL
- 0.03x
- Beta
- 0.58
Pipeline stages · 4 programs
Ralinepag
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Inhaled Treprostinil
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
10 GE Xenokidney
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GGTA1 KO Thymokidney
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 3 | Ralinepag | PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease | — | enrolling by invitation |
| 2027-11 Estimated 50% readout ~2028-01-15 | Phase 3 | Inhaled Treprostinil | Progressive Pulmonary Fibrosis, Interstitial Lung Disease | — | recruiting |
| 2028-10 Estimated 50% readout ~2028-11-15 | Phase 1/2 | 10 GE Xenokidney | ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation | — | recruiting |
| 2029-03 Estimated 50% readout ~2029-04-15 | Phase 1/2 | GGTA1 KO Thymokidney | ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation | — | recruiting |
Catalyst news & presentations · 14
- 2027Guided 40%PDUFAPDUFAralinepag · FDA decision on NDA for ralinepag in PAHSEC 8-K
- 2027Guided 40%PDUFAPDUFATyvaso · FDA decision on sNDA for nebulized Tyvaso in IPFSEC 8-K
- 2026Guided 40%readoutPhase 3Tyvaso · Topline data from TETON 1 Phase 3 trial in IPFSEC 8-K
- 2026Guided 40%readoutralinepag · ADVANCE OUTCOMES data in PAHSEC 8-K
- second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)ralinepag · NDA submission to FDASEC 8-K
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)Tyvaso · sNDA submission for nebulized Tyvaso in IPFSEC 8-K
- by the end of this summerGuided 70%regulatory submissionFiled (NDA/BLA)Tyvaso · sNDA submission to FDA for priority reviewSEC 8-K
- 2026-07-29Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026readoutPhase 3Tyvaso · Topline data readout from TETON-1 study.SEC 8-K
- 2025readoutmiroliverELAP · Data readout for miroliverELAP in acute liver failureSEC 8-K
- 2025trial initiationsecondaryUKidney · First IND clearance for UKidney xenotransplantationSEC 8-K
- 2025enrollment completesecondaryralinepag · Study close for ADVANCE OUTCOMES trial in PAHSEC 8-K
- 2025readoutPhase 3Tyvaso · Topline data from TETON 2 Phase 3 trial in IPFSEC 8-K
- September 28, 2025conferencedata presentationsecondaryPhase 3Tyvaso · Presentation of additional TETON-2 results at European Respiratory Society Congress.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $663 (+26% upside) · 13 analysts
- 2026-07-10B of A SecuritiesNeutral
- 2026-07-07RBC CapitalOutperform
- 2026-05-07RBC CapitalOutperform
- 2026-05-07Wells FargoEqual-Weight → Overweight
- 2026-04-10Morgan StanleyEqual-Weight
- 2026-03-31Wells FargoEqual-Weight
Competitors — idiopathic pulmonary fibrosis
- ABBVAbbVie Inc.$451.1B · D2
- TRVITrevi Therapeutics, Inc.$2.5B · D1
- SNDXSyndax Pharmaceuticals Inc$1.9B · D5
- AVLNAvalyn Pharma Inc.$1.3B · D4
- MNKDMANNKIND CORP$1.2B · D0
- CTNMContineum Therapeutics, Inc.$334M · D2
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- RNTXRein Therapeutics, Inc.$72M · D10
- TVRDTvardi Therapeutics, Inc.$25M · D4
- GRIGRI Bio, Inc.$3M · D6
Recent news
- 2026-07-23United Therapeutics (NASDAQ: UTHR) appoints Victor Dzau to board - Stock Titan
- 2026-07-23United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors - Financial Times
- 2026-07-23United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors - Business Wire
- 2026-07-22United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan
- 2026-07-22United Therapeutics to report Q2 2026 results on August 5 - scanx.trade
- 2026-07-22United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026 - Business Wire
- 2026-07-21United Therapeutics CEO Rothblatt sells $5.05m in stock - Investing.com
- 2026-07-21United Therapeutics (UTHR) CEO executes 9,500-share option exercise and sale - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.